Chief, Hepatopancreaticobiliary Surgery Service, Department of Surgery | Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center | |
United States, New York, New York | |
Nov 19, 2026 | |
|
Job details
About Us: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursueour missionat MSK and around the globe. Exciting Opportunity at MSK Memorial Sloan Kettering Cancer Center (MSK) is seeking an accomplished academic surgeon and leader to serve as Chief of the Hepatopancreaticobiliary (HPB) Surgery Service in the Department of Surgery. The Chief will lead an eight-surgeon Service with a broad academic mission encompassing exceptional clinical care, research, education, innovation, and program development. The next Chief will assume leadership at a particularly important time of institutional growth, creating substantial opportunities to expand established programs, develop new clinical and research programs, and broaden access to specialized HPB surgical care across MSK's network. Role Overview
Key Requirements
Core Skills
Application Interested applicants should submit a curriculum vitae and a letter of interest to Dr. Julio Garcia Aguilar, Chief Attending, Department of Surgery (garciaaj@mskcc.org), and copy Valentina Salkow, MBA, Associate Director, Office of the Chief Physician Executive (salkowv@mskcc.org). About the Opportunity The HPB Surgery Service at MSK offers a distinctive opportunity to lead a high-volume, academically rigorous surgical oncology program at a moment of significant institutional growth. Expansion of operating room and inpatient capacity, continued development of surgery across MSK's network, deep multidisciplinary research programs, and a strong institutional commitment to innovation provide an exceptional platform for the next Chief to expand established programs, develop new ones, and shape the future of HPB surgical oncology at MSK. The Service integrates complex cancer care with clinical and translational research, significant participation in the Pancreatic Cancer SPORE, advanced fellowship education, and a broad commitment to surgical innovation. The next Chief will have the opportunity to build on these strengths while defining new clinical, scientific, and educational priorities for the Service. Pay Range: $790,000 - $1,300,000 Helpful links:
Physician compensation is based on multiple variables. This range represents annual salary only and does not include supplemental performance-based pay or any one-time payments that eligible candidates may be offered at the time of hire. Pay Range: $0.00 - $10,000,000.00 FSLA Status: ExemptClosing: At MSK, we believe in fair, competitive pay that reflects your job, experience, and skills. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision. Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment. | |
Nov 19, 2026